

(IGTP), Badalona, Spain

<sup>b</sup>Servicio de Cardiología y Unidad Coronaria, Hospital Universitario Germans Trias i Pujol, Badalona, Spain

<sup>c</sup>Department of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

<sup>d</sup>Minerva Institute for Medical Research, Helsinki, Finland

<sup>e</sup>Emergency Medicine, University of Helsinki, Department of Emergency Care, Helsinki University Hospital, Helsinki, Finland

<sup>f</sup>CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain

<sup>g</sup>Departamento de Medicina, Universidad Autónoma de Barcelona (UAB), Barcelona, Spain

\* Corresponding author:

E-mail address: [abayesgenis@gmail.com](mailto:abayesgenis@gmail.com) (A. Bayes-Genis).

Available online 22 November 2018

REFERENCES

1. Harjola VP, Lassus J, Sionis A, et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. *Eur J Heart Fail.* 2015;17:501–509.
2. Andersson P, Gidlöf O, Braun OO, et al. Levels of liver-specific miR-122 is massively increased in a porcine cardiogenic shock model and attenuated by hypothermia. *Shock.* 2012;37:234–238.
3. Zhang ZW, Li H, Chen SS, Li Y, Cui ZY, Ma J. MicroRNA-122 regulates caspase-8 and promotes the apoptosis of mouse cardiomyocytes. *Braz J Med Biol Res.* 2017;2:e5760.
4. Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure. *Circulation.* 2007;116:258–267.
5. Devaux Y, Mueller M, Haaf P, et al. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. *J Intern Med.* 2015;277:260–271.
6. Tijssen AJ, Creemers EE, Moerland PD, et al. MiR 423-5p as a circulating biomarker for heart failure. *Circ Res.* 2010;106:1035–1039.

<https://doi.org/10.1016/j.rec.2018.10.008>  
1885-5857/

© 2018 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

**Endovascular Treatment of Recurrent Chylopericardium: In Vivo Demonstration of Chylopericardial Connections**



**Tratamiento endovascular del quilopericardio recurrente: demostración in vivo de conexiones quilopericárdicas**


To the Editor,

A 53-year-old Caucasian woman was admitted to hospital for increasing dyspnea on exertion and episodes of near fainting. Echocardiography revealed pericardial effusion with evidence of tamponade. The chylous nature of the fluid was confirmed by the high level of triglycerides and by a cholesterol–triglyceride ratio, which was characteristically less than 1. Cytology demonstrated an abundance of lymphocytes. Surgical pericardial window was performed. Repeat echocardiography revealed recurrent severe effusion, for which a pericardial catheter was kept in place to enable continuous drainage. When the patient was placed on a low


fat diet enriched with medium-chain triglycerides, drainage was reduced but was persistent.

The patient underwent extensive evaluation to identify the cause of the chylous pericardium. Routine laboratory tests demonstrated normal blood counts, electrolytes, liver function, lipid profile, serum urea, serum creatinine, serum calcium, and lactate dehydrogenase. There was no sign of systemic inflammatory reaction. Computed tomography (CT) of the chest revealed no obstruction to the thoracic duct. Pericardial fluid cultures were repeatedly negative for a bacterial cause. Tuberculosis was excluded by a negative Mantoux test and by repeat cultures and microscopic examination of specimens from the pericardial effusion.

Unfortunately, severe bilateral pleural effusion developed after withdrawal of the pericardial catheter. After multidisciplinary team discussion, the patient underwent surgical ligation of the thoracic duct. After initial improvement, the patient had persistent bilateral pulmonary effusion and moderate pericardial effusion.



**Figure 1.** Lymphography showing ligation of the thoracic duct by surgical clips (A–B–C, stars). A2–B2 show spontaneous extravasation from the iodinated drops from the lymphatic system into the pericardium (arrows) by periliac and pericava retroperitoneal injection of lymphatic contrast (ethiodized oil; C: arrowheads).



**Figure 2.** A: CT scan showing the cisterna chyli. B: Needle puncturing the cisterna chyli. Videos 1 and 2 of the Supplementary data show in vivo lymphographic recording of spontaneous leakage of lymphatic system particles into the pericardium after injection of ethiodized oil contrast into the right inguinal lymph node, demonstrating a connection between both the lymphatic system and the pericardium.

Thus, we used a percutaneous approach aiming to reduce the chylopericardial communication by selective embolization.

Lymphography was attempted through the right inguinal lymph node, injecting 4 cc of Lipiodol (ethiodized oil, Guerbert USA, Bloomington, IN, USA). We observed peri-iliac and pericaval retroperitoneal lymph node repletion, filling the cisterna chyli and the efferent ducts developing the origin of the thoracic duct, properly ligated by surgical clips. We confirmed a mild contrast extravasation into the pericardium (Figure 1 and Videos 1 and 2 of the supplementary data), demonstrating a leak from the retrocrural lymph nodes. We were able to selectively record the stained microparticles moving through the pericardium, providing in vivo confirmation of the connection, and explaining the continuous recurrent pericardial effusion despite surgical ligation of the thoracic duct.

The first embolization procedure was performed after lymphography through the right inguinal lymph node with 4 cc lipiodol (ethiodized oil). We observed repletion of the peri-iliac, pericaval and cisterna chyli lymphatic system, confirming the stoppage at the surgical clips (thoracic duct). We identified a mild leakage through the retrocrural lymph nodes. Using CT-guided direct puncture, the cisterna chyli was embolized with 2 cc of acrylate comonomer glubran (biodegradable synthetic surgical glue). A repeat procedure was performed 1 month later, through the same access. The cisterna chyli was still patent and thus we confirmed an incomplete previous embolization. We performed a second CT-guided direct puncture of the cisterna, injecting 0.5 cc of glubran.

Chylopericardium can be a consequence of thoracic and cardiac surgery, chest trauma, mediastinal tumors, radiotherapy, tuberculosis, and subclavian vein thrombosis.<sup>1–6</sup> Primary idiopathic chylopericardium was first described by Groves and Effler in 1954.<sup>1</sup> It is a rare clinical entity characterized by the accumulation of chyle within the pericardial cavity without a definitive cause.<sup>1–6</sup> Most cases occur in children or young adults, nearly 40% are asymptomatic, and tamponade is uncommon (5%–8%). Although the exact pathophysiology of primary chylopericardium has not been established, reflux of chylous fluid into the pericardial space has been suggested as the etiology.<sup>3–5</sup> The cisterna chyli is not easily identified on CT or magnetic resonance images due to its small size and lack of specific position and can be misidentified with lymphatic or venous structures (Figure 2). Damage to the thoracic duct valves and the communication of the thoracic duct to the pericardial lymphatic system or abnormally elevated pressure in the thoracic duct could cause chylous fluid reflux. As described in this patient, conservative treatment of primary chylopericardium is rarely successful. Thus, surgical ligation and excision of the thoracic duct

just above the diaphragm is required,<sup>4–6</sup> combined with partial pericardiectomy.<sup>4–6</sup> However, several patients have recurrent chylopericardium. Nearly 40% of patients have 2 or multiple channels instead of a single thoracic duct.<sup>5,6</sup> Moreover, it is sometimes the result of multiple lymphatic connections from retrocrural lymph nodes rather than a single efferent channel from the cisterna chyli,<sup>5</sup> as in our patient. This might explain why ligation of the thoracic duct was ineffective.

In our case, this might be the result of elevated pressure in the thoracic duct below the surgical ligation and subsequent increased flow through the connections toward the pericardium (and pleura). Percutaneous approaches have been proposed,<sup>3–6</sup> as performed in our patient. Since percutaneous treatment does not preclude surgical treatment if it fails, it is reasonable to propose a percutaneous approach as the initial treatment for thoracic duct lesions. This combined approach, percutaneous and surgical, might be necessary in many patients with recurrent chylopericardium or chylothorax. Surgical glue was used to embolize the cisterna chyli as it has been shown to be effective for embolization of small structures. Alternative embolization options could have been the application of microcoils or microspheres.<sup>6</sup> They are released through a microcatheter placed in the thoracic duct, sealing while withdrawing the microcatheter from the cranial position toward the cisterna chyli.<sup>6</sup> We provide valuable evidence of connections between the chylous system and the pericardium, demonstrated by in vivo fluoroscopy recording in the case of a 53-year-old woman with primary idiopathic chylopericardium presenting as cardiac tamponade.

In conclusion, percutaneous embolization of these connections can be helpful in this complex disease.

#### APPENDIX. SUPPLEMENTARY DATA

Supplementary data associated with this article can be found in the online version, at <https://doi.org/10.1016/j.rec.2018.11.008>.

Eduardo Alegría-Barrero,<sup>a,b,\*</sup> Álvaro Villalba,<sup>c</sup> Marco A. Blázquez,<sup>a,b</sup> Fátima Hermoso,<sup>d</sup> Juan Ruiz-García,<sup>a,b</sup> and Rocío Segoviano<sup>e</sup>

<sup>a</sup>Facultad de Ciencias de la Salud, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain

<sup>b</sup>Servicio de Cardiología, Hospital Universitario de Torrejón, Madrid, Spain

<sup>c</sup>Servicio de Radiología Intervencionista, Hospital Universitario de Torrejón, Madrid, Spain

<sup>d</sup>Servicio de Medicina Interna, Hospital Universitario de Torrejón, Madrid, Spain

<sup>e</sup>Servicio de Cirugía Torácica, Hospital Universitario de Torrejón, Madrid, Spain

\* Corresponding author:

E-mail address: [eduar.alegria@gmail.com](mailto:eduar.alegria@gmail.com) (E. Alegría-Barrero).

Available online 15 December 2018

**REFERENCES**

1. Groves LK, Effler DB. Primary chylopericardium. *N Engl J Med.* 1954;250:520–523.
2. Courtney M, Ayyagari RR. Idiopathic chylopericardium treated by percutaneous thoracic duct embolization after failed surgical thoracic duct ligation. *Pediatr Radiol.* 2015;45:927–930.

3. Schild HH, Simon B, Kuhl CK, et al. Percutaneous treatment of idiopathic chylopericardium. *J Vasc Interv Radiol.* 2009;20:842–846.
4. Akamatsu H, Amano J, Sakamoto T, Suzuki A. Primary chylopericardium. *Ann Thorac Surg.* 1994;58:262–266.
5. Phang K, Bowman M, Phillips A, Windsor J. Review of thoracic duct anatomical variations and clinical implications. *Clinical Anatomy.* 2013;27:637–644.
6. Pamarthi V, Stecker MS, Schenker MP, et al. Thoracic Duct Embolization and Disruption for Treatment of Chylous Effusions: Experience with 105 Patients. *J Vasc Interv Radiol.* 2014;25:1398–1404.

<https://doi.org/10.1016/j.rec.2018.11.008>  
1885-5857/

© 2018 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

**Coronary Lithoplasty: Initial Experience in Coronary Calcified Lesions**



**Litoplastia coronaria: experiencia inicial en lesiones calcificadas**

**To the Editor,**


Coronary lithoplasty is a novel treatment that uses high-energy mechanical pulses to break up calcium deposits in atherosclerotic heart disease. These pulses, known as *shockwaves*, are also used to break up calcium in other locations, especially the kidneys (lithotripsy). Their use in the heart is very new and there have been very few reported cases.<sup>1,2</sup>

Coronary lithoplasty involves the use of a nylon ball that, once positioned at the target site, is connected to an external unit that generates pulsatile mechanical waves lasting microseconds. The

pulses are emitted on demand and deliver an intermittent pressure of 50 to 60 atm to the vessel wall. This pressure is 3 to 4 times higher than that achieved using other devices. Balloon size must be such to achieve a balloon to artery ratio of 1:1, as the mechanical energy is generated and transmitted along the vessel wall when the balloon makes contact with the arterial intima.<sup>1</sup> As the waves travel along the wall and through the connective tissue, they cause microfractures in the calcified tissues, allowing good lesion expansion and correct stent placement.<sup>2</sup>

We present the cases of 3 patients with multivessel coronary artery disease in whom 6 severely calcified lesions were successfully treated with coronary lithoplasty. The 3 patients all had characteristics that typically call for interventional treatment: advanced age and functional class, high surgical risk, previous revascularization, and a high probability of rotational atherectomy.

The lithoplasty balloon was successfully used to treat all



**Figure 1.** A: Calcified, tortuous circumflex artery with distal, medial, and proximal lesions (asterisks). B: The intravascular ultrasound (IVUS) catheter could not be advanced. C: Application of the side-branch anchor technique did not allow advancement of the lithoplasty balloon. D: Underexpansion of the 2.5-mm noncompliant (NC) balloon in the medial area helped advance the catheter extender and move the lithoplasty balloon forward (E). E: Unsuccessful dilation with 40 pulses. F: Opening of lesion after 60 pulses. G: Outcome after placement of 4 drug-eluting stents (DES).